Epizyme, Inc. (EPZM)

[stockguard]

Upgrade for October 2nd, 2018

Epizyme analyst commentary at SunTrust Epizyme price target raised to $25 from $20 at SunTrust. SunTrust analyst Peter Lawson raised his price target on Epizyme to $25 and kept his Buy rating, citing the FDA decision for a partial clinical hold lift on tazemetostat enrollment. The analyst notes that the company has not announced any substantial changes to the trial design or patient population, but rather will increase patient monitoring after updating its exclusion criteria for new patient enrollment. Lawson contends that the New Drug Application submission for tazemetostat in the treatment of epithelioid sarcoma expected in the first half of 2019 remains on track.